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ABSTRACT
The neurochemical changes occurring between the preweanling period
and adolescence could be crucial for understanding the role development plays
in the manifestation of psychotic behaviors. N-ethoxycarbonyl-2-ethoxy-1,2dihydroquinoline (EEDQ) fully attenuates the DA agonist-induced behaviors of
adult rats, while potentiating the DA agonist-induced locomotor activity of
preweanling rats. My specific hypotheses were as follows: (1) Systemically
administered EEDQ would block the cocaine-induced locomotor activity of adult
rats. (2) Systemically administered EEDQ would potentiate the cocaine-induced
locomotion of preweanling rats. (3) EEDQ would increase the Emax values (a
measure of D2 receptor sensitivity) of preweanling rats, but not adolescent or
adult rats. And, (4) EEDQ would reduce dorsal striatal β-arrestin-2 (ARRB2) and
GRK6 levels (measures of D2 receptor sensitivity) of preweanling rats.
Behavioral results were as expected, because EEDQ attenuated the locomotion
of adult and adolescent rats, while EEDQ potentiated locomotor activity of
preweanling rats. EEDQ enhanced the GTPγS binding of preweanling rats, while
depressing ARRB2 levels. These results are consistent with the overarching
hypothesis that EEDQ causes DA supersensitivity in preweanling rats. Thus, it is
here proposed that EEDQ inactivates a significant number of D2 receptors in
preweanling rats, but that the remaining D2 receptors are supersensitive and
capable of mediating a potentiated locomotor response.
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CHAPTER ONE
INTRODUCTION
The dopamine (DA) system primarily mediates motor movement,
cognition, and emotional behavior (Keeler, Pretsell, & Robbins, 2014). Activation
of the DA system causes distinct actions depending on which receptors are
targeted. For example, under- or over-stimulation of D1 receptors results in mood
and cognitive impairments (Avery & Krichmar, 2015); whereas, overproduction of
D2 receptors in the nucleus accumbens (NAc) may cause psychotic behaviors to
emerge (Yoon, Minzenberg, Raouf, D’Esposito, & Carter, 2013). D3 receptors,
which are preferentially found in the hypothalamus, limbic areas, substantia
nigra, and the ventral tegmental area (Stahl, 2017), regulate cognition, mood,
and motivation, and are responsible for schizophrenic-like symptoms (Maramai,
et al., 2017). In addition, Parkinson’s disease results from a loss of DA
containing neurons in the nigrostriatal pathway (Graumann et al., 2002). Thus,
studying DA receptors is crucial for understanding neuropsychiatric disorders
related to DA system functioning.
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CHAPTER TWO
DOPAMINE MEDIATED BEHAVIORS IN ADULT RATS

Behavioral Effects of Direct D1 Receptor Agonists
Agonist and antagonist drugs are useful tools for understanding the role
DA receptor subtypes play in behavior (Keeler et al., 2014). For example,
systemic administration of the partial D1 receptor agonist, SKF 38393, induces
oral movements, grooming and locomotor activity in adult rats and mice (Desai,
Terry, & Katz, 2005; Neisewander, Ong, & McGonigle, 1995). Administration of
the full D1 receptor agonist SKF 82958 also increases locomotor activity in adult
rats (Charntikov et al., 2011). The anatomical locus of these effects includes the
NAc, because microinjecting SKF 38393 into this structure induces locomotor
activity in adult rats (Charntikov et al., 2011; Meyer, 1993; Neisewander et al.,
1995).

Behavioral Effects of Direct D2 Receptor Agonists
Systemic administration of selective D2 receptor agonists, such as
quinpirole or bromocriptine, typically increases locomotion in rats and mice
(Hoffman & Wise, 1992; Wise & Carlezon, 1994); however, treatment with low
doses of a direct D2 receptor agonist actually inhibits locomotor activity
(Bradbury, Cannon, Costall, & Naylor, 1984). The reason for this biphasic effect
is interesting, since low doses of quinpirole stimulate autoreceptors, thereby
reducing DA synthesis and/or release and, as a consequence, decrease
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locomotor activity (Eilam, Golani, & Szechtman, 1989). At high doses, quinpirole
directly stimulates postsynaptic receptors and produces locomotor activity (Eilam
& Szechtman, 1989; Neisewander et al., 1995).

Effects of Combined Direct D1 and D2 Receptor Stimulation
Although stimulating D1 or D2 receptors alone induces locomotor activity
and other behaviors, combined stimulation of D1 and D2 receptors causes a
unique pattern of behavior (for a review, see Arnt, 1987). For example, systemic
administration of both SKF 38393 and quinpirole, at low doses, induces
locomotor activity and some rearing behaviors (Ikemoto, 2002). At high doses,
co-administration of SKF 39383 and quinpirole causes more intense behaviors,
including head-down sniffing, gnawing, biting, and other stereotypies (Ikemoto,
2002). Microinjecting both D1 and D2 agonists into the caudate-putamen (CPu)
induces intense stereotypies, but no locomotion (Bordi & Meller, 1989; Breese et
al., 1987; Waszczak, Martin, Finlay, Zahr, & Stellar, 2002).

Behavioral Effects of Indirect DA Agonists
D1 and D2 receptors play an important role in the locomotor activating
effects of psychomotor stimulants, such as cocaine and amphetamine (Barret,
Miller, Dohrmann, & Caine, 2004; Cabib, Castellano, Cestari, Filibeck, & PuglisiAlegra, 1991; Dias, Carey, & Carrera, 2006). When cocaine is acutely
administered, DA transporters located on the presynaptic membrane are
inhibited, which results in an excess of DA in the synaptic cleft (Cabib et al.,
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1991; Henry, Hu, & White, 1998). This excess DA stimulates D1 and D2
receptors and induces behavioral effects. When administered at low to moderate
doses, cocaine increases the locomotor activity of adult rats (Kita, Shiratani,
Takenouchi, Fukuzako, & Takigawa, 1999). Not surprisingly, when administered
at high doses, cocaine causes intense stereotypies (Kita et al., 1999). Although
sometimes working through different mechanisms (e.g., altering DA release
characteristics), other psychomotor stimulants (e.g., amphetamine) also stimulate
locomotor activity and stereotypies by increasing extracellular DA levels (Wise &
Carlezon, 1994).

Behavioral Effects of Direct D1 Receptor Antagonists
Systemic administration of SCH 23390 blocks quinpirole-induced
behaviors like sniffing, yawning, and locomotor activity (McDougall, Crawford, &
Nonneman, 1992). The fact that a D1 receptor antagonist (SCH 23390) blocks
the behavioral effects of a D2 receptor agonist (quinpirole) suggests that
stimulation of the D1 receptor is crucial for the expression of D2 receptormediated behaviors (Delfs & Kelley, 1990). Some of these effects are mediated
by the NAc, since microinjecting SCH 23390 into the NAc significantly reduces
the behavioral effects of quinpirole (Bordi & Meller, 1989). Likewise, infusing
SCH 23390 into the ventral lateral striatum decreases the oral behaviors, but not
the locomotor activity, of amphetamine-treated rats (Delfs & Kelley, 1990). The
latter result suggests that D1 and D2 receptors in the ventral lateral striatum
mediate stereotypy and not locomotion.
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Behavioral Effects of Direct D2 Receptor Antagonists
Not surprisingly, D2 receptor antagonists block the behavioral effects
caused by a D2 receptor agonist. For example, systemic administration of
sulpride significantly reduces the behavioral effects caused by microinjecting
quinpirole into the NAc (Bordi & Meller, 1989; McDougall et al., 1992). Systemic
treatment with a D2 antagonist also blocks the grooming behavior caused by
SKF 39393 administration (McDougall et al., 1992). Thus, a functional D2 system
appears necessary for the expression of D1-mediated behaviors.
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CHAPTER THREE
DOPAMINE-MEDIATED BEHAVIORS IN RAT PUPS

Changes in catecholamine levels lead to a higher probability of psychiatric
disorders, addiction, and motoric problems (Antonopoulos, Dori, Dinopoulos,
Chiotelli, & Parnavelas, 2002). For example, early exposure to psychostimulant
drugs can promote drug addiction in adulthood due to chemical changes
occurring at a younger postnatal age. Byrnes and Bruno (1994) suggest that
early cocaine exposure activates compensatory mechanisms that persist into
adulthood and lead to addiction. In the developing brain, DA also plays a crucial
role in mediating sensory motor information, such as locomotor activity and
stereotypy. Drugs that act as agonists and antagonists allow us to determine DA
receptor function, while microinjection techniques allow us to examine the locus
of drug effects.

Behavioral Effects of Direct D1 Receptor Agonists
Systemic administration of SKF 38393, a partial D1 receptor agonist,
increases probing, head lifting, and locomotion in rats at postnatal day (PD) 3
through PD 10 (Moody & Spear, 1992). At PD 20, SKF 38393 enhances
grooming, oral movements, and locomotor activity (McDougall et al., 1992).
Microinjecting the full D1 receptor agonist SKF 82958 directly into the CPu
increases both locomotor activity and stereotypy in preweanling rats (Charntikov
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et al., 2011). Lower doses of SKF 82958 preferentially induce locomotor activity,
whereas higher doses increase stereotypic behaviors (Charntikov et al., 2011).

Behavioral Effects of Direct D2 Receptor Agonists
Systemic administration of quinpirole, a selective D2 agonist, increases
locomotor activity, yawning, sniffing, and rearing during the preweanling period
(McDougall et al., 1992). For example, quinpirole produces forward locomotion
by as early as PD 3, and even greater amounts of locomotor activity at PD 10
and PD 21 (Moody & Spear, 1992). Although selective D2 receptor agonists
increase locomotor activity, oral movements are inhibited by quinpirole (DerGhazarian et al., 2012). While most of these effects mimic what occurs in adults,
D2 receptor agonists can sometimes function as antagonists in preweanling rats,
but only during conditions of low dopaminergic tone (Byrnes & Bruno, 1994;
Yoshida, Baella, Stuebner, Crawford, & McDougall, 2006).

Effects of Combined Direct D1 and D2 Receptor Stimulation
During early ontogeny, systemic administration of NPA, a non-selective
D1/D2 receptor agonist, typically enhances stereotypy and decreases grooming,
but these effects are highly dependent on dose and age (McDougall et al., 1992).
At moderate doses of NPA, co-stimulation of D1 and D2 receptors increases
nonstereotypic behaviors in PD 10 pups, such as wall climbing, roll curling, and
forward locomotion (McDougall et al., 1992). At PD 17 and PD 20, rats also show
increased locomotion after moderate doses of NPA (Der-Ghazarian et al., 2012).
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In adult rats, locomotion is replaced by stereotypy when moderate or high doses
of NPA are administered (Bordi, Carr, & Meller, 1989).

Indirect DA Agonist-Induced Behavior
Psychomotor stimulants, such as cocaine and amphetamine, cause an
increase in locomotor activity in young rats (Anker & Carroll, 2010). Cocaine
sensitivity is higher in preweanling rats (PD 5 and PD 20) than adults, perhaps
due to a greater percentage of D2High receptors in the striatum (McDougall,
Eaton, Mohd-Yusof, & Crawford, 2015). Sensitivity to cocaine begins to drop
during adolescence, as the percentage of D2High receptors gradually declines to
adult-like levels (McDougall et al., 2015).

Behavioral Effects of Direct D1 Receptor Antagonists
Systemic administration of SCH 23390, a D1 receptor antagonist, blocks
the behavioral effects of the D1 receptor agonist SKF 38393 in preweanling rats
(Charntikov et al., 2011). Systemic administration of SCH 23390 also blocks
quinpirole-induced behaviors, such as sniffing, yawning, and locomotor activity
(Chausmer & Katz, 2002; Moody & Spear, 1992; Sobrian, Jones, Varghese, &
Holson, 2003), thus showing that in both preweanling and adults rats a functional
D1 receptor system is necessary for the expression of D2-mediated behaviors.
SCH 23390 also attenuates cocaine-induced behavioral effects in preweanling
rats (Charntikov et al., 2011). These actions may be mediated by the CPu, since
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microinjecting SCH 23390 into the CPu significantly reduces the behavioral
impact of quinpirole in preweanling rats (Charntikov et al., 2011).

Behavioral Effects of Direct D2 Receptor Antagonists
Systemic administration of a D2 receptor antagonist (e.g., raclopride)
blocks the behavioral effects of a D2 receptor agonist (e.g., quinpirole) in
preweanling rats (Charntikov et al., 2011). Systemic administration of a D2
receptor antagonist also blocks the locomotor activity caused by D1 receptor
agonists or cocaine (Byrnes & Bruno, 1994; Chausmer & Katz, 2002; McDougall
et al., 1992). On PD 18, microinjecting SKF 82958 and quinpirole directly into the
CPu increase locomotion, head down sniffing, and repetitive motor movement,
while infusing raclopride into the CPu fully attenuates these agonist-induced
behavioral effects (Charntikov et al., 2011).

Summary
In preweanling rats, D1 and D2 receptors interact when mediating
unlearned behaviors. For example, D1 receptors are necessary for the full
expression of D2-mediated locomotor activity, whereas a functional D2 receptor
system is necessary for the full expression of D1-mediated behaviors
(McDougall, Arnold, & Nonneman, 1990). This conclusion is not surprising since
a similar relationship exists between D1 and D2 receptor systems in adult rats
(Clark & White, 1987).
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CHAPTER FOUR
DOPAMINE PHARMACOLOGY

Synthesis
DA, norepinephrine (NE) and epinephrine are all part of a monoamine
subfamily called the catecholamines. The rate-limiting step in the production of
the catecholamines is tyrosine hydroxylase. Tyrosine hydroxylase converts
tyrosine into levopoda (L-DOPA). L-DOPA is then converted into the
neurotransmitter DA by the enzyme dopa decarboxylase (Ugrumov, 2006).

Storage and Release
DA is stored in vesicles in the presynaptic terminal. DA exocytosis is
triggered by an influx of Ca2+, whereby vesicles fuse to the membrane wall and
release DA into the synaptic cleft (Cooper, Bloom, & Roth, 2003).

Reuptake
Free DA in the synaptic cleft is returned to the presynaptic terminal via an
ATP-dependent DA reuptake transporter (DAT) (Zanettini et al., 2018). This freefloating DA is then repackaged in vesicles for reuse. Excess DA in the
presynaptic terminal is metabolized by monoamine oxidase (Zanettini et al.,
2018).
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Receptors
DA receptors are classified into the D1 and D2 family of receptors. The D1
family includes D1 and D5 receptors, whereas the D2 family of receptors contains
the D2, D3, and D4 subtypes (Cooper et al., 2003). Stimulating the D1 family of
receptors activates the enzyme adenylyl cyclase, which increases cyclic
adenosine monophosphate (c-AMP) levels (Cooper et al., 2003). Conversely,
stimulating the D2 family of receptors inhibits adenylyl cyclase and reduces
cAMP, thereby modulating the phosphorylation of K+ channels and inhibiting
Ca2+ channels (Ogren, Hall, Kohler, Magnusson, & Sjostrand, 1986).
DA receptors exist in high and low affinity states. For example, DA
sensitivity is associated with the proportion of D2 receptors in a high affinity state
(Seeman, 2008). Work by Seeman et al. (2005) suggests that an excess of
D2High receptors produces DA supersensitivity, which can cause DA agonists to
have an exaggerated behavioral response. An excess of D2High receptors may be
responsible for many neuropsychiatric disorders, including psychosis and drug
addiction (Seeman et al., 2005).

Presynaptic vs. Postsynaptic Receptors
In addition to the various receptor subtypes, DA receptors can be
differentiated according to whether they are located postsynaptically or
presynaptically. DA postsynaptic receptors are G protein-coupled receptors that
alter K+ permeability (Onali, Mosca, & Olianas, 1992). For example, stimulation of
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postsynaptic D1 receptors causes IPSP’s in the down-stream neuron (Onali et
al., 1992). In contrast, stimulation of presynaptic D2 autoreceptors decreases DA
synthesis and release through G protein-mediated mechanisms (Onali et al.,
1992).

Major Dopamine Pathways in the Basal Ganglia
The ventral tegmental area (VTA) is part of a motivational pathway
projecting to various brain areas, such as the NAcc, hypothalamus, hippocampus
and neocortex (Antonopoulos et al., 2001). The substantia nigra pars compacta
(SNPC) is the starting point of another ascending pathway projecting to the CPu.
Neurons projecting from the VTA and SNPC release DA at their target locations.
Thus, stereotypy and motor movement are partially mediated by the nigrostriatal
DA pathway projecting from the SNPC to the CPu (Bordi & Meller, 1989; Delfs &
Kelley, 1990); whereas, locomotion, motivation and reward are partially mediated
by the mesolimbic DA pathway projecting from the VTA to the NAcc and cortical
structures (Delfs, Schreiber, & Kelley, 1990; Gong, Neil, & Justice, 1996; Meyer,
Van Hartesveldt, & Potter, 1993)

Intrinsic Non-Dopaminergic Pathways in the Basal Ganglia
There are two pathways interconnecting the structures of the basal
ganglia: the direct pathway and the indirect pathway (for reviews, see Alexander,
DeLong, & Strick, 1986; Parent & Hazrati, 1995a,1995b). The direct pathway is
formed from long axonal projections going from the CPu to the globus pallidus
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internal segment (GPi) and substantia nigra pars reticulata (SNRP). The indirect
pathway is comprised of a series of neurons projecting from the CPu to the
globus pallidus external segment (GPe), to the subthalamic nucleus, and
terminating at the GPi and SNPR. The direct pathway facilitates locomotor
activity, reward, and reinforcement, while the indirect pathway suppresses the
same behaviors (Dobbs et al., 2016).
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CHAPTER FIVE
DOPAMINE PHARMACOLOGY: DEVELOPMENT
DA acts on D1-like and D2-like receptors to regulate motor and non-motor
functions (Mishra, Singh, & Shukla, 2018). Both D1 and D2 receptors must be
fully functional in order to express DA-mediated behaviors (Grigoriadis et al.,
1996). As mentioned above, DA receptors are found both pre- and
postsynaptically, and become functionally mature at different stages of
development (Grigoriadis et al., 1996; Hedner & Lundborg, 1985; Parish,
Finklestein, Drago, Borrelli, & Horne, 2001). Presynaptic DA receptors are not
present at PD 4 and do not become fully mature and functional until PD 28
(Grigoriadis et al., 1996; Hedner & Lundborg, 1985). More specifically, PPP,
which is a DA agonist that preferentially binds to autoreceptors, increases
locomotor activity at PD 4 but decreases locomotion at PD 28, thus indicating
that only postsynaptic receptors are functional at the earlier age. Indeed, D2
autoreceptors are not fully functional until the 4th postnatal week, but are
neurochemically available by PD 17 (Lin & Walters, 1994).
In terms of postsynaptic D1 and D2 receptors, there is a progressive
increase in the availability of striatal D1 and D2 receptors from birth through the
preweanling period (Kuperstein, Eilam, & Yavin, 2008; McDougall et al., 2014;
Rao, Molinoff, & Joyce, 1991; Teicher, Anderson, & Hostetter, 1995). During
adolescence, there is an overproduction of D1 and D2 receptors, which gradually
declines as rats enter adulthood (Andersen, 2003; McDougall et al., 2015).
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In addition to these receptor changes, other DA elements develop across
early ontogeny, including DAT, VMAT2, DA content, tyrosine hydroxylase
activity, adenylyl cyclase activity, and D1 and D2 receptor activity (Broaddus &
Bennett, 1990; Giorgi et al.,1987; Kuperstein et al., 2008; Tarazi & Baldessarini,
2000). Work done by Kuperstein et al. (2008), showed that there is a linear
increase in tyrosine hydroxylase levels in the substantia nigra across ontogeny.
VMAT2, DAT content, and DA levels in the CPu also exhibit a linear increase
from PD 0 to PD 30 (Kuperstein et al., 2008). The ontogeny of adenylyl cyclase is
similar to the ontogeny of D1 receptors, as adenylyl cyclase activity gradually
increases across the preweanling period and into adolescence, and then
gradually declines into adulthood (Broaddus & Bennett, 1990).
As mentioned before, DA receptor numbers increase across the
preweanling period, peak in adolescence, and gradually decline into adulthood
(Andersen, 2003). In terms of neuronal functionality, the ontogeny of nigrostriatal
DA neurons has been examined using single-unit extracellular
electrophysiological methods. Although the basal discharge rate, conduction
velocity, and firing pattern of nigrostriatal neurons of 4- and 5-week-old rats was
similar to adults, 2-week-old-rats differed significantly in all three of these
physiological characteristics (Freeman, 2008). Specifically, the conduction
velocity and basal discharge rate of nigrostriatal neurons were significantly
reduced in 14-day-old rats when compared to adults. Thus, Freeman (2008)
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concluded that physiological properties of nigrostriatal DA neurons are in a
dynamic state of flux during the preweanling period.
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CHAPTER SIX

EEDQ
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) is an irreversible
DA receptor antagonist that permanently inactivates DA receptors. EEDQ is
typically used to study the time course of DA receptor replacement (Crawford,
McDougall, Rowlett, & Bardo, 1992; Crawford, Rowlett, McDougall, & Bardo,
1994), but EEDQ can also be used to examine the role of DA receptors in
behavior (Meller, Bordi, & Bohmarker, 1989). Although EEDQ affects a variety of
receptor types, specificity can be attained by preinjecting rats with reversible
selective DA antagonists (e.g., raclopride on SCH 23390) before EEDQ
treatment. In this way, D1 or D2 receptors can be selectively protected from
EEDQ-induced inactivation (Cameron & Crocker, 1989; Giorgi & Biggio, 1990;
Meller, Bohmaker, Goldstein, & Friedhoff, 1985).
Importantly, EEDQ produces dramatically different behavioral effects in
preweanling and adult rats (McDougall et al., 1992; McDougall, Crawford, &
Nonneman, 1993). In adult rats, EEDQ eliminates DA agonist-induced behaviors.
For example, EEDQ fully attenuated the NPA-induced locomotor activity of adult
rats when measured one or two days after EEDQ administration (McDougall et
al., 1992; Meller et al., 1989). Similarly, EEDQ abolishes apomorphine-induced
stereotypies and quinpirole-induced rotational behavior in adult rats (Cameron &
Crocker, 1989; Giorgi & Biggio, 1990). DA agonist-induced behaviors began to
re-emerge when assessed four or more days after EEDQ treatment (Meller et al.,
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1989).
In complete contrast, EEDQ does not block the DA agonist-induced
locomotor activity of preweanling rats. For example, pretreating 17-day-old rats
with EEDQ did not attenuate the acute locomotor activating effects of NPA
(McDougall et al., 1992; 1993). Indeed, EEDQ often potentiates the D2 agonistinduced locomotor activity of younger animals. In preweanling rats, infusing NPA,
quinpirole, or cocaine into the CPu actually stimulates greater amounts of
locomotor activity in EEDQ-pretreated rats than controls (Der-Ghazarian et al.,
2012, 2014). Studies using selective DA agonists, as well as D1 and D2 receptor
protection, have shown that the D2 receptor is responsible for EEDQ’s agedependent behavioral effects (Der-Ghazarian et al., 2014). Thus, inactivating DA
receptors with EEDQ cause a paradoxical potentiation of D2 agonist-induced
locomotor activity in preweanling rats, while EEDQ blocks the DA agonistinduced behaviors of adult rats.
The reason for EEDQ’s surprising age-dependent behavior effects is
uncertain. The most obvious possibility is that EEDQ does not cause DA receptor
loss in preweanling rats. This explanation is not correct because systemic
administration of EEDQ (7.5 mg/kg) causes a substantial decline (preweanling
47%; adult 40%) in the D2 receptors of both age groups (McDougall et al., 2014).
When microinjected into the CPu, EEDQ causes significantly greater reductions
in the D2 receptors of preweanling rats (54%) than adult rats (35%) (DerGhazarian et al., 2012). Regardless, it is clear that EEDQ’s ability to potentiate
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the DA agonist-induced behaviors of preweanling rats cannot be explained by
slight differences in the total amount of DA receptor inactivation.
Another possible explanation for EEDQ’s paradoxical behavioral effects is
the presence of a large D2 receptor reserve in young rats. In other words,
preweanling rats may possess a large excess of unused DA receptors, thus a
50% reduction of D2 receptors, for example, would be insufficient to impact
behavior. Such a D2 receptor reserve does exist in adult rats (Meller, Bohmaker,
Namba, Friedhoff, & Goldstein, 1987; Meller et al., 1985; Rosengarten,
Schweitzer, & Friedhoff, 1989), but there is no evidence for such a reserve in
preweanling rats. For example, D2 receptors in the CPu show a linear increase
across the preweanling period and into adolescence (Rao et al., 1991), thus
leaving little room for a receptor reserve.
A third possible explanation is that the DA receptors remaining after
EEDQ-induced inactivation exist in a high affinity state, and that these high
affinity D2 receptors are significantly more prevalent in preweanling rats than
adult rats. If true, these excess D2High receptors could be responsible for the
potentiated locomotor response observed in preweanling rats (McDougall et al.,
2014). Indeed, DA supersensitivity typically occurs when there is an increase in
the percentage of D2High receptors (Seeman et al., 2005). To examine the effects
of EEDQ on high affinity D2 receptors, McDougall et al. (2014) measured the
D2High receptors of preweanling, adolescent, and adult rats one day after vehicle
or EEDQ (7.5 mg/kg) pretreatment. As hypothesized, the percentage of D2High
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receptors in the CPu was significantly greater in EEDQ-treated preweanling rats
than adults. Therefore, this receptor binding data is consistent with the
hypothesis that EEDQ’s ability to potentiate DA agonist-induced behaviors is due
to an excess of D2High receptors.
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CHAPTER SEVEN
SUMMARY AND HYPOTHESES
In summary, EEDQ fully attenuates the DA agonist-induced behaviors of
adult rats. Surprisingly, preweanling rats do not respond to EEDQ in the same
manner as adult rats, because EEDQ either potentiates or does not affect the DA
agonist-induced behaviors of preweanling rats. The neurochemical changes that
occur between the preweanling period and adolescence could be crucial to
understanding the role of development in the manifestation of psychotic
behaviors.
There are a number of explanations for EEDQ’s age-dependent
paradoxical actions. For example, EEDQ may not reduce the DA receptor levels
of preweanling rats and/or preweanling rats may possess a large D2 receptor
reserve. There is little evidence for these possibilities. Alternatively, EEDQ may
cause a relative increase in the percentage of D2High receptors in preweanling
rats when compared to adults. Such an effect has been observed before
(McDougall et al., 2014), but it is uncertain whether this EEDQ-induced increase
in the percentage of D2High receptors is actually capable of mediating behavioral
or neurochemical effects. The purpose of this thesis was to more fully examine
the latter issue.
My specific hypotheses were as follows: (1) Systemically administered
EEDQ would block the cocaine-induced locomotor activity of adult rats. (2)
Systemically administered EEDQ would potentiate the cocaine-induced
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locomotion of preweanling rats. The latter behavioral effect was presumed to be
due to an increased percentage of D2High receptors in preweanling rats. To test
whether EEDQ does, in fact, increase D2 receptor sensitivity a GTPγS assay
was conduced. GTPγS, which is a measure of receptor/G protein coupling, is one
of the most common measures of D2 receptor supersensitivity (Geurts, Herman,
Cumps, & Maloteaux, 1999; Seeman, Battaglia, Corti, Corsi, & Bruno, 2009). (3) I
hypothesized that EEDQ would increase the Emax and pEC50 values (a measure
of D2 receptor sensitivity) of preweanling rats, but not adolescent or adult rats. βarrestin (ARRB2) and GRK6 regulate DRD2, a super family of G protein receptors
(Oda et al., 2015). When G-protein phosphorylation is triggered, GRK6
phosphorylates the receptor while ARRB2 causes internalization of the
phosphorylated receptors. Importantly, ARRB2 and GRK6 levels should be
depressed in situations of high D2 receptor sensitivity (Hurle, 2001; Oda et al.,
2015). (4) For this reason, I hypothesized that EEDQ would decrease ARRB2
and GRK6 levels in preweanling rats, but not in adolescent or adult rats.
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CHAPTER EIGHT
METHODS

Subjects
Subjects were 432 preweanling, adolescent, and adult rats. Male (N = 96)
and female (N = 48) adult rats were purchased from Charles River (Hollister,
CA); whereas, male (N = 96) and female (N = 48) preweanling rats, as well as
male (N = 96) and female (N = 48) adolescent rats, were born and bred at
California State University, San Bernardino (CSUSB). Litters were culled to 10
pups on postnatal day (PD) 3 and weaned on PD 23. Preweanling rats were kept
with the dam and littermates, whereas adolescent and adult rats were grouphoused with conspecifics. All rats were housed on racks in large polycarbonate
maternity cages (56 × 34 × 22 cm) with wire lids. Food and water was freely
available. The colony room was maintained at 22–23 °C and kept under a 12
L:12 D cycle. Subjects were cared for according to the “Guide for the Care and
Use of Laboratory Animals” (National Research Council, 2010) under a research
protocol approved by the Institutional Animal Care and Use Committee of
CSUSB.

Apparatus
For preweanling (PD 18), adolescent (PD 40), and adult (PD 85) rats,
behavioral testing was done in activity monitoring chambers that consist of acrylic
walls, a plastic floor, and an open top (Coulbourn Instruments, Whitehall, PA).
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Each chamber includes an X–Y photobeam array, with 16 photocells and
detectors, that was used to determine distance traveled (a measure of locomotor
activity). In order to equate for differences in body size (see Campbell, Lytle, &
Fibiger, 1969; Shalaby & Spear, 1980), preweanling rats were tested in smaller
chambers (26 × 26 × 41 cm) than adolescent and adult rats (41 × 41 × 41 cm).

Drugs
Cocaine was dissolved in saline; whereas, EEDQ was dissolved in a 50%
DMSO solution [1:1 (v/v) in distilled water]. Drugs were purchased from Sigma
(St. Louis, MO). Drugs were injected intraperitoneally (IP) at a volume of 2.5
ml/kg (preweanling rats) and 1 ml/kg (adolescent and adult rats).

Behavior Procedure
Prior to the start of behavioral testing, male and female rats were
randomly assigned to treatment groups. At 24 h prior to testing (i.e., on PD 17,
PD 39, or PD 84), rats were injected with vehicle or EEDQ (2.5 or 7.5 mg/kg) and
then returned to their home cage. After 24 h (i.e., on PD 18, PD 40, or PD 85),
rats (n = 8 per group) were taken to the experimental room and injected with
saline or 15 mg/kg cocaine immediately before being placed in the testing
chambers for 120 min. Locomotor activity was measured.

35
Homogenate [ S] GTPγS Binding Assay

On PD 17, PD 39, and PD 84, male rats were injected with vehicle or
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EEDQ (2.5 or 7.5 mg/kg). After 24 h, rats (n = 8 per group) were killed by rapid
decapitation and CPu sections were dissected bilaterally on an ice-cold
dissection plate and stored at -80 °C. On the day of assay, tissue was thawed on
ice, and crude membrane homogenates were homogenized in 100 volumes of 50
mM Tris-HCl buffer (pH 7.4) for approximately 20 s using a Brinkman Polytron.
Homogenates were centrifuged at 20,000 × g for 30 min. The pellet was
resuspended in 100 volumes of the same buffer and centrifuged again at 20,000
× g for 30 min. The final pellet was suspended in approximately 20 volumes of
buffer (pH 7.4) and incubated for 30 min at 30 °C to remove endogenous
transmitter. Protein concentrations for the final pellet were determined using the
Bio-Rad Protein Assay with BSA as the standard.
35

Agonist-effect curves of [ S] GTPγS binding were performed in assay
buffer (50 mM Tris-HCl, 120 mM NaCl) containing 30 μM GDP, 10–20 μg protein,
along with DA (1 nM to 1 mM) or equivalent volumes of water. Nonspecific
binding was determined in the presence of 30 μM cold GTPγS. The tubes were
35

preincubated for 15 min at 30 °C, and then 0.1 nM [ S] GTPγS was added.
35

Following the addition of [ S] GTPγS, tubes were incubated for an additional 30
min at 30 °C. The incubation period was ended by filtering the contents of the
35

tubes using glass fiber filters. Net agonist-stimulated [ S] GTPγS binding values
were calculated by subtracting basal binding values (without agonist) from
agonist-stimulated values (with agonist) and dividing by basal values. Agonist
potency (pEC50) and agonist efficacy (Emax) were determined by iterative
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nonlinear regression fitting using Prism (Graph Pad Software).

ARRB2 and GRK6
On PD 17, PD 39, and PD 84, male rats were injected with vehicle or
EEDQ (2.5 or 7.5 mg/kg). After 24 h, rats (n = 8 per group) were killed by rapid
decapitation and CPu sections were dissected bilaterally on an ice-cold
dissection plate and stored at -80 °C. Frozen CPu sections were weighed and
sonicated into a 20 nM tris buffer containing 1% NP40 and a protease inhibitor
cocktail. After sonication, samples were centrifuged at 10,000 × g for 15 min at 4
°C. Protein concentrations for the final pellet were determined using the Bio-Rad
Protein Assay with BSA as the standard.
ARRB2 and GRK6 were assessed using enzyme-linked immunosorbant
assay (ELISA) kits (CUSABIO, CBS-EL002135RA and CBS-EL009927RA).
Briefly, various dilutions of standard ARRB2 or GRK6 were made and test
samples were diluted in sample diluent (1% BSA, 0.125% Tween-20 in PBS) and
added to the wells of precoated assays plates. The plates were incubated for 2 h
at 37 °C. Liquid from each well was discarded and 100 μL of biotin-antibody
(ARRB2 or GRK6) was added. The plates were incubated at 37 °C for 1 h. Plates
were aspirated and washed three times with wash buffer (PBS, 0.1%Tween-20),
after which 100 μL HRP-avidin was added to each well and the plates were again
be incubated at 37 °C for 1 h. After the incubation, the plates were washed five
times and TMB substrate was added to each well and incubated at 37 °C for 1530 min in the dark. To stop the color development, stop solution was added. To
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determine optical density values, absorbance readings at 450 nm, with a
wavelength correction reading at 540 nm, was made using a micro plate reader
(Multiskan Sky, Thermo Scientific, Waltham, MA).

Statistical Analyses
All main effects, interactions, and post hoc tests were considered
significant at p<0.05. Litter effects were minimized by assigning no more than
one rat from each litter to a particular condition (Holson & Pearce, 1992). For the
behavioral experiment, distance traveled data were analyzed using a repeated
measures analysis of variance (ANOVA) 3 x 3 x 2 x 12 (age x pretreatment x
drug x time block). Mauchly’s test was used to detect violations of the sphericity
assumption. When violations of sphericity were detected the Huynh-Feldt Epsilon
statistic was used to make corrections. When appropriate, Tukey tests were used
for making planned and post hoc comparisons. For Tukey calculations involving
time block interactions, the mean square error term was calculated using
separate one- or two-way ANOVAs.
For the GTPγS binding assay a logarithmic transformation of Emax and
pEC50 was conducted (Y’=log10Y). GTPγS (Emax and pEC50), ARRB2, and GRK6
data were analyzed using separate 3 x 3 (age x pretreatment) between-subjects
ANOVAs. Tukey tests were used for making planned and post hoc comparisons
(p<0.05).
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CHAPTER NINE
BEHAVIORAL RESULTS

Overall Analysis
Overall, female rats exhibited significantly more locomotor activity than
male rats [Sex main effect, F1,252=27.10, p<.001]. Based on this finding, the
behavioral data of male and female rats were analyzed separately in the final
statistical analyses.

Ontogenetic Differences in the Locomotor Activity of Male Rats
(Collapsed Over Time Blocks)
Among male rats, the pre- and posttreatment factors interacted with age to
affect locomotor activity [Age x Pre x Post interaction, F4,126 = 15.24, p<.001]. In
saline-treated preweanling rats, EEDQ had no effect on basal locomotor activity;
however, in adolescent and adult male rats both doses of EEDQ (2.5 and 7.5
mg/kg) reduced the basal locomotor activity of saline-treated male rats (see left
graph, Figure 1) [Pretreatment effects, F2,21=18.04, p<.001, F2,21=7.82, p<.001,
and Tukey tests p<.05, respectively].
The pattern of results changed when rats were injected with cocaine. For
example, preweanling male rats pretreated with 7.5 mg/kg EEDQ exhibited a
potentiated locomotor response when injected with cocaine (see upper graphs,
Figure 1) [Pretreatment effect, F2,21=11.39, p<.001]. A nearly opposite effect
occurred in adolescent and adult male rats, because 2.5 and 7.5 mg/kg EEDQ
reduced cocaine-induced locomotor activity (see middle and lower right graphs,
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Figure 1) [Pretreatment effects, F2,21=17.59, p<.001, F2,21=91.30, p<.001, and
Tukey tests p<.05, respectively].
A separate statistical analysis comparing the effects of saline and cocaine
in vehicle-pretreated male rats showed that 15 mg/kg cocaine caused greater
locomotor activity in adolescent and adult rats than preweanling rats
[Posttreatment x Age interaction, F2,42=10.82, p<.001, and Tukey tests, p<.05],
while the basal locomotor activity of saline-treated male rats did not differ
according to age (compare open bars, Figure 1).The same statistical analysis
showed that cocaine significantly increased the locomotor activity of adolescent
and adult rats, but not preweanling rats. Importantly, an ANOVA including only
preweanling male rats indicated that 15 mg/kg cocaine did, in fact, increase the
locomotor activity of the younger age group [Posttreatment effect, F1,14 = 22.98,
p<.001, and Tukey tests, p<.05].

Ontogenetic Differences in the Locomotor Activity of Male Rats
(Time-Dependent Effects)
Overall, an omnibus ANOVA showed that age interacted with pretreatment,
posttreatment, and time variables to affect distance traveled scores [Age × Pre ×
Post interaction, F4,126 =15.24, p<0.001; aAge × Pre × Post × Time Block
interaction, F19,610 =1.60, p<0.05]. To further break apart the statistically
significant three- and four-way interactions, separate lower order ANOVAs were
conducted at each age.
Among saline-treated preweanling male rats, EEDQ did not differentially
affect distance traveled scores across time blocks; however, 7.5 mg/kg EEDQ
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potentiated the locomotor activity of rats treated with 15 mg/kg cocaine on time
blocks 5–12 (see upper right graph, Figure 2) [aPre × Post × Time block
interaction, F13,265 =1.91, p<0.05; and Tukey tests, p<0.05]. Separate analyses of
saline-treated adolescent male rats indicated that 2.5 mg/kg EEDQ depressed
locomotion on time blocks 1, 2, 4, and 11; whereas, 7.5 mg/kg EEDQ reduced
locomotion on time blocks 1–6 and time blocks 10 and 11 (see left middle graph,
Figure 2) [aPre × Time block interaction, F19,204 =4.51, p<0.001; and Tukey tests,
p<0.05]. Likewise, 2.5 and 7.5 mg/kg EEDQ decreased the distance traveled of
cocaine-treated adolescent male rats on all 12 time blocks (see right middle
graph, Figure 2) [aPre × Time block interaction, F5,53 =3.31, p<0.05; and Tukey
tests, p<0.05]. Similar to adolescents, 2.5 and 7.5 mg/kg EEDQ decreased the
distance traveled scores of cocaine-treated adult male rats (time blocks 1–12)
and saline-treated adult male rats (time blocks 1–3 and time block 7) (see lower
graphs, Figure 2) [aPre × Post × Time block interaction, F8,158 =3.67, p<0.001;
and Tukey tests, p<0.05].
Comparisons across age showed that preweanling male rats in the
vehicle-saline control group exhibited less locomotor activity than similarly
treated adolescent (time block 1) and adult male rats (time blocks 1–3 and time
block 7) (compare left graphs, Figure 2) [aAge × Pre ×Time block interaction,
F28,351 =2.22, p<0.001; and Tukey tests, p<0.05]. No age differences were
apparent when EEDQ-pretreated male rats were tested after an injection of
saline. When injected with cocaine, vehicle-pretreated adolescent and adult
male rats had greater distance traveled scores than preweanling male rats on
time blocks 2–12 (compare right graphs, Figure 2) [aAge × Pre ×Time block
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interaction, F17,261 =2.20, p<0.01; and Tukey tests, p<0.05]. Conversely, cocainetreated preweanling male rats injected with 7.5 mg/kg EEDQ had greater
distance traveled scores than similarly treated adult male rats on time blocks 1–
12 and similarly treated adolescent male rats on time blocks 6–12 (Tukey tests,
p<0.05).

Ontogenetic Differences in the Locomotor Activity of Female Rats
(Collapsed Over Time Blocks)
Among female rats, the pre- and posttreatment factors interacted with age
to affect locomotor activity [Age x Pre x Post interaction, F4,126 = 6.68, p<.001]. In
female preweanling rats treated with saline, EEDQ caused a significant increase
in basal locomotor activity (see upper right graph, Figure 3) [Pre effect,
F2,21=16.38, p<.001, and Tukey tests, p<.05]. However, in adolescent and adult
female rats, both doses of EEDQ (2.5 and 7.5 mg/kg) decreased locomotor
activity of saline-treated rats (see middle and lower right graphs, Figure 3) [Pre
effects, F2,21=14.22, p<.001, F2,21=31.44, p<.001, and Tukey tests, p<.05,
respectively].
Results changed when female rats were injected with cocaine. In
preweanling female rats, 7.5 mg/kg EEDQ caused a marginally significant
increase in the locomotor activity of cocaine-treated rats (see upper right graph,
Figure 3) [Pre effect, F2,21=3.40, p<.052, and Tukey tests, p<.05]. However, in
adolescent and adult female rats both doses of EEDQ significantly decreased
cocaine-induced locomotor activity (see middle and lower right graphs, Figure 3)
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[Pre effects, F2,21=50.38, p<.001, F2,23=22.92, p<.001, and Tukey tests, p<.05,
respectively].
As was done with male rats, a separate ANOVA comparing the effects of
saline and cocaine in vehicle-pretreated female rats was conducted. Adolescent
and adult female rats given 15 mg/kg cocaine exhibited greater locomotor activity
than preweanling female rats [Posttreatment x Age interaction, F2,42=10.26,
p<.001, and Tukey tests, p<.05]. In addition, cocaine-treated female rats of all
ages exhibited significantly greater distance traveled scores than saline-treated
female rats of the same age [Tukey test, p<.05].

Ontogenetic Differences in the Locomotor Activity of Female Rats
(Time-Dependent Effects)
Overall, an omnibus ANOVA showed that age interacted with pretreatment,
posttreatment, and time variables to affect distance traveled scores [Age × Pre ×
Post interaction, F4,126 =6.68, p<0.001; aAge × Pre × Post × Time Block
interaction, F19,610 =1.49, p<0.05]. To further break apart the statistically
significant three- and four-way interactions, separate lower order ANOVAs were
conducted at each age.
Among saline-treated preweanling female rats, 7.5 mg/kg EEDQ
increased locomotion on time blocks 2-8, 10 and 11 (see upper left graph, Figure
4) [aPre × Time block interaction, F19,204 =1.13, p<0.001; and Tukey tests,
p<0.05]. Moreover, 7.5 mg/kg EEDQ potentiated the locomotor activity of female
rats treated with 15 mg/kg cocaine on time blocks 6, 7, 9-12 (see upper right
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graph, Figure 4) [aPre × Post × Time block interaction, F13,265 =3.98, p<0.05; and
Tukey tests, p<0.05].
Separate analyses of saline-treated adolescent female rats indicated that
2.5 and 7.5 mg/kg EEDQ depressed locomotion on time blocks 1-4, 6, 7, 9, 10
and 12 (see left upper graph, Figure 4) [aPre × Time block interaction, F19,204
=2.58, p<0.001; and Tukey tests, p<0.05]. EEDQ at both doses (2.5 and 7.5
mg/kg) decreased the distance traveled scores of cocaine (time blocks 1–12) and
saline (time blocks 1–5 and time block 7-11) treated adult female rats (see lower
graphs, Figure 4) [aPre × Post × Time block interaction, F8,158 =4.31, p<0.001;
and Tukey tests, p<0.05].
Comparisons across age showed that female rats in the vehicle-saline
control group exhibited an increase in locomotor activity with aging increase.
Adolescent (time block 1-4, 6, 7, 9, 10, and 12) and adult (time blocks 1–5 and 711) female rats had more locomotor activity than preweanling rats (compare left
graphs, Figure 4) [aPre ×Time block interaction, F28,351 =5.13, p<0.001; and
Tukey tests, p<0.05]. There were significant age differences when EEDQ (7.5
mg/kg)-pretreated female rats were tested after an injection of cocaine.
Specifically, cocaine-treated preweanling rats exhibited more locomotor activity
than adolescent and adults female rats on time block 6, 7, and 9-12 [aPre ×Time
block interaction, F28,351 =7.41, p<0.001; and Tukey tests, p<0.05].

33

[35S]GTPγS Binding
GTPγS binding was significantly greater in preweanling rats than adults
(Table 1) [Age main effect, F2,54=3.98, p<0.05; and Tukey tests, p<0.05]. Both
doses of EEDQ (2.5 and 7.5 mg/kg) increased Emax values [Drug main effect,
F2,54=15.54, p<0.001; and Tukey tests, p<0.05]. The efficacy of GTPγS binding of
EEDQ-treated preweanling rats was greater than either vehicle-treated
preweanling rats or EEDQ-treated adult rats [Age × Pretreatment interaction,
F2,57=3.81; p<0.05, and Tukey tests, p<0.05]. EEDQ also increased Emax values
of adolescent rats relative to same-age vehicle controls [Tukey tests, p<0.05].
pEC50 binding did not vary according to age or pretreatment condition (Table 2).
ARRB2 Levels
Both doses of EEDQ (2.5 and 7.5 mg/kg) reduced ARRB2 levels [Pretreatment
main effect, F2,86=5.92, p<0.05; and Tukey tests, p<0.05]. There were age
differences in which AARB2 levels increased with age. Specifically, adults had
the highest levels of ARRB2, preweanling rats had the lowest levels, and
adolescent rats had moderate levels of ARRB2 that were significantly different
from both younger and older rats [Age main effect, F2,86=75.28, p<0.001; and
Tukey tests, p<0.05]. The Age × Pretreatment interaction was not statistically
significant [p=0.21].
GRK6 Levels
EEDQ did not affect GRK6 levels. Adult rats had significantly greater GRK6
levels than both of the younger age groups [Age main effect, F2,86=72.25,
p<0.001; and Tukey tests, p<0.05]
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Figure 1. Ontogenetic Differences in the Locomotor Activity of Male Rats
(Collapsed Over Time Blocks)
Mean (SEM) distance traveled scores of preweanling, adolescent, and adult
male rats (n = 8 rats per group) injected with saline or cocaine (15 mg/kg, IP)
immediately before testing. On the pretreatment day, which occurred 24 h
earlier, rats had been injected with vehicle or EEDQ (2.5 or 7.5 mg/kg, IP).
‘a’ indicates a significant difference from vehicle-treated rats of the same age given the same post
injection (i. e., saline or cocaine). ‘b’ indicates a significant difference from cocaine-treated
adolescent and adult rats that were pretreated with vehicle. ‘c’ indicates a significant difference
from saline-treated rats of the same age that were pretreated with vehicle.
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Figure 2. Ontogenetic Differences in the Locomotor Activity of Male Rats (TimeDependent Effects)
Mean (SEM) distance traveled scores of preweanling, adolescent, and adult
male rats (n = 8 rats per group) injected with saline or cocaine (15 mg/kg, IP)
immediately before testing. On the pretreatment day, which occurred 24 h
earlier, rats had been injected with vehicle or EEDQ (2.5 or 7.5 mg/kg, IP).
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Figure 3. Ontogenetic Differences in the Locomotor Activity of Female Rats
(Collapsed Over Time Blocks)
Mean (SEM) distance traveled scores of preweanling, adolescent, and adult
male rats (n = 8 rats per group) injected with saline or cocaine (15 mg/kg, IP)
immediately before testing. On the pretreatment day, which occurred 24 h
earlier, rats had been injected with vehicle or EEDQ (2.5 or 7.5 mg/kg, IP).
‘a’ indicates a significant difference from vehicle-treated rats of the same age given the same post
injection (i. e., saline or cocaine). ‘b’ indicates a significant difference from cocaine-treated
adolescent and adult rats that were pretreated with vehicle. ‘c’ indicates a significant difference
from saline-treated rats of the same age that were pretreated with vehicle.
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Figure 4. Ontogenetic Differences in the Locomotor Activity of Female Rats
(Time-Dependent Effects)
Mean (SEM) distance traveled scores of preweanling, adolescent, and adult
female rats (n = 8 rats per group) injected with saline or cocaine (15 mg/kg, IP)
immediately before testing. On the pretreatment day, which occurred 24 h
earlier, rats had been injected with vehicle or EEDQ (2.5 or 7.5 mg/kg, IP).
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Table 1. Mean (SEM) Efficacy (Emax) of NPA-Stimulated [35S]GTPγS Specific
Binding in the Dorsal Striatum of EEDQ-Treated Preweanling, Adolescent, and
Adult rats (n = 7 per group)
Pretreatment

Age
________________________________________________
Preweanling

Adolescent

Vehicle

13.21 (2.30)

16.47 (2.76)

2.5 mg/kg EEDQ

40.76 (5.36) cd

7.5 mg/kg EEDQ

37.12 (6.94) cd

x̅(P+A+A)

Adult
16.02 (1.16)

15.23 (1.24)

28.04 (3.84) e

22.33 (2.92)

30.38(2.86) b

29.51 (3.06) e

26.07 (3.71)

30.90(2.86) b

x̅ (V+E+E)
30.36 (3.96) a 24.68 (2.21) 21.47 (1.80)
________________________________________________________________
‘a’ Significantly different from adult rats [Tukey tests, p < 0.05].
‘b’ Significantly different from vehicle-treated rats [Tukey tests, p < 0.05].
‘c’ Significantly different from vehicle-treated preweanling rats [Tukey tests, p < 0.05].
‘d’ Significantly different from EEDQ-treated adult rats [Tukey tests, p < 0.05].
‘e’ Significantly different from vehicle-treated adolescent rats [Tukey tests, p < 0.05].
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Table 2. Mean (SEM) Potency (pEC50) of NPA-Stimulated [35S]GTPγS Specific
Binding in the Dorsal Striatum of EEDQ-Treated Preweanling, Adolescent, and
Adult Rats (n = 7 per group)
Pretreatment

Age
________________________________________________
x̅(P+A+A)

Preweanling

Adolescent

Adult

Vehicle

6.93 (0.33)

6.63 (0.51)

6.04 (0.29)

6.74 (0.18)

2.5 mg/kg EEDQ

6.54 (0.42)

6.01 (0.42)

6.97 (0.52)

6.37 (0.22)

7.5 mg/kg EEDQ

6.74 (0.13)

6.46 (0.36)

6.05 (0.42)

6.35 (0.26)

x̅ (V+E+E)
6.53 (0.23)
6.51 (0.25)
6.42 (0.20)
________________________________________________________________
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Table 3. Mean (SEM) -Arrestin-2 Levels (pg/mg protein) in the Dorsal Striatum
of EEDQ-Treated Preweanling, Adolescent, and Adult Rats (n = 10–12 per
group)

Pretreatment

Age
________________________________________________
Adult

x̅(P+A+A)

Preweanling

Adolescent

Vehicle

577.1 (54.2)

915.2 (59.5)

1223.3 (75.9) 925.0 (60.4)

2.5 mg/kg EEDQ

476.7 (46.6)

858.7 (49.2)

1015.4 (44.8) 778.4 (49.0)

7.5 mg/kg EEDQ

526.8 (54.6)

831.1 (39.0)

944.6 (33.8)

754.8 (40.3) a

x̅ (V+E+E)
526.8 (30.2) bc 866.9 (28.2) b 1073.0 (39.8)
_______________________________________________________________
‘a’ Significantly different from vehicle-treated rats [Tukey tests, p < 0.05].
‘b’ Significantly different from adult rats [Tukey tests, p < 0.05].
‘c’ Significantly different from adolescent rats [Tukey tests, p < 0.05].
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Table 4. Mean (SEM) GRK6 Levels (pg/mg protein) in the Dorsal Striatum of
EEDQ-Treated Preweanling, Adolescent, and Adult Rats (n = 10–12 per group)

Pretreatment

Age
________________________________________________
x̅(P+A+A)

Preweanling

Adolescent

Adult

Vehicle

342.6 (36.7)

620.9 (35.4)

758.6 (54.7)

585.6 (40.0)

2.5 mg/kg EEDQ

337.6 (19.2)

628.9 (15.2)

686.4 (46.6)

551.0 (33.0)

7.5 mg/kg EEDQ

372.6 (27.2)

624.8 (35.2)

669.7 (45.8)

546.7 (30.8)

x̅ (V+E+E)

352.3 (16.2) ab

624.9 (17.0) a

708.3 (28.9)

‘a’ Significantly different from adult rats [Tukey tests, p < 0.05].
‘b’ Significantly different from adolescent rats [Tukey tests, p < 0.05].
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CHAPTER TEN
DISCUSSION

Behavioral Effects of EEDQ
It is well established that EEDQ attenuates locomotor activity in adult rats
by reducing the amount of D2 receptors available (Der-Ghazarian et al., 2014;
McDougall et al., 2015). In adolescent rats, the EEDQ-induced reduction in
locomotor activity is similar to the decline observed in adult rats (McDougall et
al., 2014). In preweanling rats, EEDQ also inactivates D2 receptors in the dorsal
striatum; however, DA agonists cause a potentiated locomotor response
(McDougall et al., 1993). An important goal of the present study was to determine
what DA receptor changes are responsible for the different locomotor effects
observed in EEDQ-treated rats across ontogeny.
Age-Dependent Behavioral Differences
In the present thesis, 15 mg/kg cocaine produced a statistically significant,
but small, increase in the locomotor activity of PD 18 rats; however, 15 mg/kg
cocaine caused a large increase in the locomotor activity of adolescent and adult
rats. Regardless of age, cocaine produced a slightly greater locomotor response
in female rats than male rats. Basal locomotor activity of preweanling rats was
reduced relative to female and male saline-treated adolescent and adult rats.
Rats treated with saline prior to EEDQ exhibited substantially different
amounts of locomotor activity depending on age. Saline-treated female
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preweanling rats injected with EEDQ showed an increase in locomotor activity on
the test day, while saline-treated female adolescent and adult rats injected with
EEDQ exhibited a decline in locomotor activity on the test day. On the other
hand, basal locomotor activity of male preweanling rats was not affected by
EEDQ, even though saline-treated adolescent and adult male rats showed a
significant reduction in locomotion after EEDQ treatment.
EEDQ also differentially affected cocaine-induced locomotor activity
depending on age. Preweanling male rats treated with cocaine exhibited a
potentiated locomotor response after EEDQ treatment. In stark contrast, adult
and adolescent rats showed the opposite effect, as EEDQ attenuated cocaineinduced locomotor activity. Likewise, female preweanling rats treated with either
dose of EEDQ (2.5 or 7.5 mg/kg) exhibited a potentiated locomotor response
when injected with cocaine. Both doses of EEDQ reduced the cocaine-induced
locomotor activity of female adolescent and adult rats.
In sum, EEDQ pretreatment (2.5 and 7.5 mg/kg) impacted locomotor
behavior across ontogeny. Among preweanling rats, both doses of EEDQ
increased the locomotor activity of cocaine-treated rats. Adolescent rats showed
a significant reduction of locomotor activity after EEDQ treatment, although
cocaine-treated adolescent rats exhibited a slight increase in distance traveled
scores when compared to saline-treated rats. Adult rats showed a similar pattern
of behavior as adolescent rats, since both doses of EEDQ (2.5 and 7.5 mg/kg)
reduced locomotor activity in cocaine-treated adults.
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Neurochemistry Results Pertaining to DA Supersensitivity
It was originally hypothesized that the increase in locomotor activity
evident in EEDQ-treated preweanling rats is due to DA receptor supersensitivity.
To assess this hypothesis we measured GTPγS binding, as well as ARRB2 and
GRK6 content, because DA receptor supersensitivity is reliably associated with
increased GTPγS binding and decreased ARRB2 and GRK6 levels (Oda et al.,
2015). Moreover, it has been established that GTPϒS binding is positively
correlated with the percentage of D2 receptors in a high affinity state (Seeman et
al., 2009). In the present thesis, EEDQ increased the GTPϒS binding of
preweanling rats, thus suggesting that EEDQ-treated rats had an excess of
D2High receptors. Adolescent and adult rats did not exhibit a similar increase in
GTPγS binding.
ARRB2 levels were also used to examine DA supersensitivity in EEDQtreated rats, because a decrease in ARRB2 and GRK6 levels indicates
supersensitivity (Hurle, 2001; Oda et al., 2015). The mechanism for this effect
has been established, as activation of the D2 receptor causes GRK6 to
phosphorylate the receptor, which, in turn, stimulates ARRB2 to bind with the G
protein/receptor complex (Del’Guidice, Lemasson, & Beaulieu, 2011; PorterStransky & Weinshenker, 2017). ARRB2 binding causes internalization of the
ligand-bound receptor, and a loss of receptor sensitivity, until the receptor is
dephosphorylated (for reviews, see Gainetdinov et al., 2017). In the present
study, ARRB2 levels increased with age. More importantly, EEDQ-treated rats,
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regardless of age, had reduced levels of ARRB2 when compared to salinetreated rats. This decline in ARRB2 levels indicated that EEDQ caused D2
receptor supersensitivity.
GRK6 levels were not significantly affected by EEDQ treatment at any
age. Although it was originally hypothesized that GRK6 levels would be reduced
in EEDQ-treated preweanling rats, the current results did not show such an
effect. Instead, GRK6 levels were elevated in adult rats relative to the younger
age groups. In sum, the EEDQ-induced increase in GTPγS binding and decrease
in ARRB2 levels are consistent with a DA supersensitivity explanation, whereas
the GRK6 data are not supportive.

Explanations of EEDQ-Induced Locomotor Potentiation in Preweanling Rats
The working hypothesis on which this thesis was based is that EEDQ
destroys a significant percentage of D2 receptors in preweanling rats, but that the
remaining D2 receptors are in a high affinity state. It is these surviving D2
receptors that we believe are responsible for the potentiated locomotor response
exhibited by EEDQ-treated preweanling rats.
Alternative explanations are available for the paradoxical cocaine-induced
locomotor responding of EEDQ-treated preweanling rats. First, EEDQ may not
cause DA receptor loss in preweanling rats. This potential explanation is not
accurate because EEDQ-treated preweanling rats exhibit a 69% reduction of
dorsal striatal D2 receptors, while adults show a 80% reduction (Crawford et al.,
1992; Crawford, Rowlett, McDougall, & Bardo, 1994; Der-Ghazarian et al., 2012).
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Although EEDQ causes a greater reduction in the percentage of D2 receptors in
adult rats, a 61% decline in the number of D2 receptors can certainly not explain
why EEDQ potentiates the cocaine-induced locomotor activity of preweanling
rats.
Second, these behavioral results could be explained by a large D2
receptor reserve existing in younger rats. This explanation postulates that some
DA receptors were inactivated by EEDQ, but an excess of spare D2 receptors
make EEDQ’s receptor inactivating effects irrelevant (Der-Ghazarian et al.,
2012). Although there is a D1 receptor reserve in adult rats (Meller et
al.,1985,1987; Rosengarten et al., 1989) there is no evidence that a D2 receptor
reserve exists in younger rats. In fact, available evidence suggests that a D2
receptor reserve is not present at any age (Meller, Goldstein, Friedhoff, &
Schweitzer, 1988).
Third, we come back to our original hypothesis that in preweanling rats,
and perhaps adults, EEDQ inactivates a significant number of D2 receptors, but
the remaining receptors exist in a high affinity state. Consistent with this idea,
EEDQ-treated preweanling rats had a greater percentage of D2High receptors
than EEDQ-treated adolescent and adult rats. The supersensitivity explanation is
further supported by results from the present thesis in which EEDQ-treated
preweanling rats had increased GTPγS binding and reduced ARRB2 levels. The
reason why EEDQ only potentiates the cocaine-induced locomotor activity of
preweanling rats, and not adolescent and adult rats, is uncertain; however, it is
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probably because EEDQ inactivates a lesser percentage of D2 receptors in
younger rats (Crawford et al., 1992; Der-Ghazarian et al., 2014; Leff, Gariano, &
Creese, 1984) and/or D2 receptors repopulate more quickly in younger rats than
adults (Kula, George, & Baldessarini, 1992; Leff et al., 1984).
Differential Effects of EEDQ on Cocaine- and Amphetamine-Induced Locomotor
Activity
An interesting aspect of the present study is that EEDQ potentiated the
cocaine-induced locomotor activity of preweanling rats (Figures 1 and 3), even
though we previously reported that EEDQ is unable to block amphetamineinduced locomotor activity in the same age group (Crawford, McDougall, &
Bardo, 1994a). Two possibilities suggest themselves: (1) Cocaine and
amphetamine have differing affinities for the DA and 5-HT transporter, and (2)
cocaine and amphetamine rely on different DA pools. Cocaine has a high affinity
for the DA, 5-HT, and noradrenergic transporters, while amphetamine and
methamphetamine only bind to the 5-HT and noradrenergic transporters (Howell
& Kimmel, 2008). This dichotomy suggests that 5-HT may contribute to the
locomotor potentiation effect observed in preweanling rats. Consistent with this
explanation, EEDQ inactivates 5-HT receptors (Kettle, Cheetham, Martin, Prow,
& Heal, 1999), and some 5-HT receptor subtypes mediate locomotor activity
(Geyer, 1996).
Perhaps of more relevance, cocaine increases extracellular DA by
blocking re-uptake of DA from vesicular stores, while amphetamine primarily
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relies on releasing newly synthesized DA from cytosolic pools (Kuczenski, 1983).
Thus, EEDQ may only attenuate locomotor activity if the indirect DA agonist
utilizes newly synthesized DA from cytosolic pools. This hypothesis is supported
by a series of studies showing that EEDQ dramatically reduces the amount of DA
in cytosolic pools (Crawford et al., 1992; Crawford, McDougall, & Bardo, 1994b).
In sum, it is possible that the different behavioral actions of amphetamine and
cocaine are a consequence of the DA pools each drug relies on.

Ontogeny of Drug Action
In a broader context, EEDQ is one of many compounds (in multiple drug
classes) that produce different behavioral effects across ontogeny (Andersen,
2003, 2005; Spear, 2000). It is likely that maturational changes in DA systems,
as well as other neurotransmitter systems, underlie age-dependent differences in
drug action. For example, various components of the DA system, including DA
content, VMAT2, and plasma membrane DA transporters, show a progressive
increase from birth into adulthood (Broaddus & Bennett, 1990; Kuperstein et al.,
2008). Moreover, D2 receptors increase from birth until the end of the
preweanling period, are dramatically overproduced during adolescence, and then
decline until adulthood age is reached (Rao et al., 1991; Teicher et al., 1995).
Consistent with these maturational changes, we found that dorsal striatal ARRB2
and GRK6 levels also increase across ontogeny. Anderson and Teicher (2000)
have proposed that the transient overproduction of D2 receptors may be of
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clinical importance for both ADHD and schizophrenia. Our current results may
also be of clinical relevance, because GRK6 and ARRB2, which are associated
with D2High receptors, show maturational changes across early ontogeny.

Sex-Dependent Behavioral Differences
Although not a novel finding, cocaine-treated adolescent and adult female
rats displayed greater locomotor activity than cocaine-treated male rats of the
same age (Der-Ghazarian et al., 2012; Festa et al., 2004; McDougall et al, 2015;
Schindler & Carmona, 2002). The behavioral differences between cocainetreated males and female rats is probably not related to cocaine
pharmacokinetics as peak cocaine values and cocaine half-life in brain vary
minimally according to sex (McDougall et al., 2018; Schindler & Carmona, 2002).
That being said, there are some active metabolites that differ between the sexes,
as cocaine-treated female rats have higher levels of ecgonine methyl ester and
benzoylecgonine than males (Schindler & Carmona, 2002). Whether these small
differences in metabolite levels can account for sex-dependent changes in
cocaine responsitivity is uncertain.
Another explanation that might account for sex-related differences in
cocaine’s actions involve gonadal hormones (Becker, 1999). Specifically,
increased estrogen levels might be responsible for differences in cocaine
sensitivity. At least two neuronal mechanisms could underlie this effect. First,
estrogen inhibits GABA which, in turn, increases DA neurotransmission (Becker,
1999; Schindler & Carmona, 2002). Second, estrogen increases DA release by
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down-regulating D2 receptor function (Bazzett & Becker, 1994). Males do not
produce as much estrogen as females; therefore, these two estrogen-based
mechanisms may explain why cocaine’s behavioral effects are more pronounced
in female rats (Becker, 1999).
In the present study, cocaine also caused a slight increase in the
locomotor activity of female preweanling rats relative to male rats. This result was
unexpected and is not consistent with many past studies showing that
psychostimulants do not differentially affect the locomotor responsiveness of
prepubertal male and female rats (Kozanian, Gutierrez, Mohd-Yusof, &
McDougall, 2012; McDougall et al., 2015, 2018; Snyder, Katovic, & Spear, 1998).
These results are also not consistent with the estrogen explanations just
discussed, since the gonadal hormone levels of prepubescent rats do not differ
according to sex.

Summary
DA dysfunction is responsible for many neuropsychiatric problems like
anorexia, insomnia, aggravation, ADHD, Tourette’s disorder, and psychosis
(Kostrzewa et al., 2018; Tatsumi, Groshan, Blakely, & Richelson, 1997). Many of
these disorders are prominent or are initially expressed during early ontogeny
(Kostrzewa et al., 2018). Adolescence is a crucial developmental period with a
unique pattern of increased DA activity in response to drugs (Spear, 2000);
whereas, the late preweanling period is analogous to late childhood, which is a
time that many DA-mediated disorders are first expressed (Smith & Morrell,
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2008). DA supersensitivity, which was a primary focus of this study, varies
across ontogeny, but appears to be especially pronounced during the
preweanling period. Accumulating evidence suggests that DA supersensitivity
may be related to an excess of D2High receptors (Seeman et al., 2009). The
consequences of excess D2High receptors are many, as D2High receptors may be
the critical mediating factor leading to psychosis (Seeman et al., 2005). Not only
do individuals with schizophrenia have an excess of D2High receptors, they also
show greater sensitivity to DA (Seeman et al., 2005). When considered together,
the present behavioral and neurochemical results suggest that DA
supersensitivity is especially pronounced during the preweanling period, which is
consistent with the onset of many neuropsychiatric disorders (Tourette’s disorder,
ADHD, etc.).
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